Biocure Technology Past Earnings Performance
Past criteria checks 3/6
Biocure Technology has been growing earnings at an average annual rate of 51.1%, while the Biotechs industry saw earnings growing at 18.6% annually. Revenues have been declining at an average rate of 17% per year.
Key information
51.1%
Earnings growth rate
52.1%
EPS growth rate
Biotechs Industry Growth | 51.1% |
Revenue growth rate | -17.0% |
Return on equity | 93.8% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biocure Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | 2 | 1 | 0 |
30 Jun 23 | 0 | 2 | 1 | 0 |
31 Mar 23 | 0 | 0 | 1 | 0 |
31 Dec 22 | 0 | 0 | 1 | 0 |
30 Sep 22 | 0 | 2 | -1 | -1 |
30 Jun 22 | 0 | 1 | 0 | -1 |
31 Mar 22 | 0 | -1 | 1 | 0 |
31 Dec 21 | 0 | -2 | 2 | 0 |
30 Sep 21 | 0 | -6 | 3 | 3 |
30 Jun 21 | 0 | -5 | 2 | 3 |
31 Mar 21 | 0 | -4 | 2 | 1 |
31 Dec 20 | 0 | -3 | 1 | 2 |
30 Sep 20 | 0 | -3 | 2 | 1 |
30 Jun 20 | 0 | -3 | 2 | 1 |
31 Mar 20 | 0 | -5 | 3 | 1 |
31 Dec 19 | 0 | -5 | 3 | 1 |
30 Sep 19 | 0 | -4 | 3 | 1 |
30 Jun 19 | 0 | -4 | 3 | 1 |
31 Mar 19 | 0 | -6 | 5 | 1 |
31 Dec 18 | 0 | -7 | 5 | 1 |
30 Sep 18 | 0 | -9 | 5 | 1 |
30 Jun 18 | 0 | -9 | 4 | 1 |
31 Mar 18 | 0 | -5 | 1 | 1 |
31 Dec 17 | 0 | -5 | 1 | 0 |
30 Sep 17 | 0 | -3 | 1 | 1 |
30 Jun 17 | 0 | -3 | 1 | 1 |
31 Mar 17 | 0 | -2 | 1 | 0 |
31 Dec 16 | 0 | -2 | 1 | 0 |
Quality Earnings: CURE has a high level of non-cash earnings.
Growing Profit Margin: Insufficient data to determine if CURE's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CURE has become profitable over the past 5 years, growing earnings by 51.1% per year.
Accelerating Growth: CURE's earnings growth over the past year (12.8%) is below its 5-year average (51.1% per year).
Earnings vs Industry: CURE earnings growth over the past year (12.8%) exceeded the Biotechs industry -34.2%.
Return on Equity
High ROE: CURE's Return on Equity (93.8%) is considered outstanding.